AstraZeneca PLC (AZN) Free Cash Flow (FCF): $9.11B
The free cash flow (FCF) for AstraZeneca PLC (AZN) is $9.11B. It is below its 12-month average by 4.32% ($9.52B).
AZN Free Cash Flow (FCF) Chart
AZN Average Free Cash Flow (FCF) Chart
AZN Current vs Average Free Cash Flow (FCF) Chart
AZN Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$9.11B
FREE CASH FLOW (FCF) AVG TTM
$9.52B
FREE CASH FLOW (FCF) AVG 3Y
$8.21B
FREE CASH FLOW (FCF) AVG 5Y
$6.47B
FREE CASH FLOW (FCF) AVG 10Y
$4.08B
FREE CASH FLOW (FCF) AVG 15Y
$4.48B
FREE CASH FLOW (FCF) AVG 20Y
$4.91B
CURRENT VS TTM AVG
-4.32%
CURRENT VS 3Y AVG
+10.93%
CURRENT VS 5Y AVG
+40.85%
CURRENT VS 10Y AVG
+123.24%
CURRENT VS 15Y AVG
+103.42%
CURRENT VS 20Y AVG
+85.57%
FCF Analysis
Free Cash Flow (TTM)
$9.11B
FCF Yield
3.20%
Price/FCF
31.2
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
AstraZeneca PLC Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The free cash flow (FCF) for AZN stock is $9.11B.
- What is the TTM average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The TTM average free cash flow (FCF) for AZN stock is $9.52B.
- What is the 3Y average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The 3Y average free cash flow (FCF) for AZN stock is $8.21B.
- What is the 5Y average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The 5Y average free cash flow (FCF) for AZN stock is $6.47B.
- What is the 10Y average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The 10Y average free cash flow (FCF) for AZN stock is $4.08B.
- What is the 15Y average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The 15Y average free cash flow (FCF) for AZN stock is $4.48B.
- What is the 20Y average free cash flow (FCF) for AstraZeneca PLC (AZN)?
- The 20Y average free cash flow (FCF) for AZN stock is $4.91B.
AstraZeneca PLC Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $11.77B |
| 2024-12-31 | $7.28B |
| 2023-12-31 | $6.57B |
| 2022-12-31 | $7.24B |
| 2021-12-31 | $3.76B |
| 2020-12-31 | $2.19B |
| 2019-12-31 | $509.00M |
| 2018-12-31 | $1.25B |
| 2017-12-31 | $1.96B |
| 2016-12-31 | $1.83B |
| 2015-12-31 | $536.00M |
| 2014-12-31 | $4.31B |
| 2013-12-31 | $5.34B |
| 2012-12-31 | $2.33B |
| 2011-12-31 | $6.52B |
| 2010-12-31 | $8.26B |
| 2009-12-31 | $8.78B |
| 2008-12-31 | $4.70B |
| 2007-12-31 | $5.83B |
| 2006-12-31 | $6.35B |
| 2005-12-31 | $5.76B |
| 2004-12-31 | $4.54B |
| 2003-12-31 | $2.13B |
| 2002-12-31 | $3.49B |
| 2001-12-31 | $443.83M |
| 2000-12-31 | $875.25M |
| 1999-12-31 | $-1.84B |
| 1998-12-31 | $34.86M |
| 1997-12-31 | $-8.27M |
| 1996-12-31 | $148.99M |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot